Answers are grounded in this paper and cite their sources.
Objective: To determine the levels of serum and salivary neopterin in acute coronary syndrome (ACS) in comparison with established biomarkers like Troponin-I and CK-MB. Background: Neopterin is the product of activated macrophage which is released by activated monocyte by cytokines during the acute phase response of ACS, can be used as a biomarker for diagnosis of ACS. Materials and methods: ACS (n = 675) individuals with or without ST-segment elevation myocardial infarction were enrolled for the study, for three years. Serum and saliva neopterin were estimating by HPLC and compared with established biomarkers like Troponin-I and CK-MB. Results: Increased serum and salivary neopterin levels were observed in patients with STEMI, NSTEMI, and UA of ACS. From the ROC analysis serum and salivary neopterin were found to be more sensitive and specific than the established biomarkers of ACS like Troponin-I and CK-MB, in diagnosing ACS. Conclusion: Neopterin being more sensitive and specific than troponin and CK-MB, can be a marker of ACS. The collection of saliva being Noninvasive salivary neopterin can be easily estimated than serum neopterin.
No takes yet. Share an insight, caveat, or question.
YV et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: